These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

299 related articles for article (PubMed ID: 21762075)

  • 21. Selective targeting p53
    Lu W; Cheng F; Yan W; Li X; Yao X; Song W; Liu M; Shen X; Jiang H; Chen J; Li J; Huang J
    Oncogene; 2017 Aug; 36(33):4719-4731. PubMed ID: 28394340
    [TBL] [Abstract][Full Text] [Related]  

  • 22. p53-Mdm2 Interaction Inhibitors as Novel Nongenotoxic Anticancer Agents.
    Nayak SK; Khatik GL; Narang R; Monga V; Chopra HK
    Curr Cancer Drug Targets; 2018; 18(8):749-772. PubMed ID: 28669344
    [TBL] [Abstract][Full Text] [Related]  

  • 23. UBE4B, a ubiquitin chain assembly factor, is required for MDM2-mediated p53 polyubiquitination and degradation.
    Wu H; Leng RP
    Cell Cycle; 2011 Jun; 10(12):1912-5. PubMed ID: 21558803
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Molecular pathways: targeting Mdm2 and Mdm4 in cancer therapy.
    Li Q; Lozano G
    Clin Cancer Res; 2013 Jan; 19(1):34-41. PubMed ID: 23262034
    [TBL] [Abstract][Full Text] [Related]  

  • 25. An overview of PROTACs targeting MDM2 as a novel approach for cancer therapy.
    Li H; Cai X; Yang X; Zhang X
    Eur J Med Chem; 2024 Jun; 272():116506. PubMed ID: 38761584
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Overexpression of Mdm2 and MdmX fusion proteins alters p53 mediated transactivation, ubiquitination, and degradation.
    Ghosh M; Huang K; Berberich SJ
    Biochemistry; 2003 Mar; 42(8):2291-9. PubMed ID: 12600196
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Inhibiting Hdm2 and ubiquitin-activating enzyme: targeting the ubiquitin conjugating system in cancer.
    Weissman AM; Yang Y; Kitagaki J; Sasiela CA; Beutler JA; O'Keefe BR
    Ernst Schering Found Symp Proc; 2008; (1):171-90. PubMed ID: 19202599
    [TBL] [Abstract][Full Text] [Related]  

  • 28. p53-Mdm2 inhibitors: patent review (2009 - 2010).
    Kamal A; Mohammed AA; Shaik TB
    Expert Opin Ther Pat; 2012 Feb; 22(2):95-105. PubMed ID: 22316395
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Parthenolide promotes the ubiquitination of MDM2 and activates p53 cellular functions.
    Gopal YN; Chanchorn E; Van Dyke MW
    Mol Cancer Ther; 2009 Mar; 8(3):552-62. PubMed ID: 19276167
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Reactivation of p53 by a specific MDM2 antagonist (MI-43) leads to p21-mediated cell cycle arrest and selective cell death in colon cancer.
    Shangary S; Ding K; Qiu S; Nikolovska-Coleska Z; Bauer JA; Liu M; Wang G; Lu Y; McEachern D; Bernard D; Bradford CR; Carey TE; Wang S
    Mol Cancer Ther; 2008 Jun; 7(6):1533-42. PubMed ID: 18566224
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Elevated MDM2 boosts the apoptotic activity of p53-MDM2 binding inhibitors by facilitating MDMX degradation.
    Xia M; Knezevic D; Tovar C; Huang B; Heimbrook DC; Vassilev LT
    Cell Cycle; 2008 Jun; 7(11):1604-12. PubMed ID: 18520179
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A new twist in the feedback loop: stress-activated MDM2 destabilization is required for p53 activation.
    Stommel JM; Wahl GM
    Cell Cycle; 2005 Mar; 4(3):411-7. PubMed ID: 15684615
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Spiro-oxindoles as a Promising Class of Small Molecule Inhibitors of p53-MDM2 Interaction Useful in Targeted Cancer Therapy.
    Gupta AK; Bharadwaj M; Kumar A; Mehrotra R
    Top Curr Chem (Cham); 2017 Feb; 375(1):3. PubMed ID: 27943171
    [TBL] [Abstract][Full Text] [Related]  

  • 34. ATM-mediated phosphorylations inhibit Mdmx/Mdm2 stabilization by HAUSP in favor of p53 activation.
    Meulmeester E; Pereg Y; Shiloh Y; Jochemsen AG
    Cell Cycle; 2005 Sep; 4(9):1166-70. PubMed ID: 16082221
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A second p53 binding site in the central domain of Mdm2 is essential for p53 ubiquitination.
    Ma J; Martin JD; Zhang H; Auger KR; Ho TF; Kirkpatrick RB; Grooms MH; Johanson KO; Tummino PJ; Copeland RA; Lai Z
    Biochemistry; 2006 Aug; 45(30):9238-45. PubMed ID: 16866370
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Recent advances on the intervention sites targeting USP7-MDM2-p53 in cancer therapy.
    Harakandi C; Nininahazwe L; Xu H; Liu B; He C; Zheng YC; Zhang H
    Bioorg Chem; 2021 Nov; 116():105273. PubMed ID: 34474304
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Molecular modeling approaches in the discovery of new drugs for anti-cancer therapy: the investigation of p53-MDM2 interaction and its inhibition by small molecules.
    Lauria A; Tutone M; Ippolito M; Pantano L; Almerico AM
    Curr Med Chem; 2010; 17(28):3142-54. PubMed ID: 20666726
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Emerging Role of MDM2 as Target for Anti-Cancer Therapy: A Review.
    Shaikh MF; Morano WF; Lee J; Gleeson E; Babcock BD; Michl J; Sarafraz-Yazdi E; Pincus MR; Bowne WB
    Ann Clin Lab Sci; 2016 Dec; 46(6):627-634. PubMed ID: 27993876
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Targeting MDM2-p53 interaction for cancer therapy: are we there yet?
    Nag S; Zhang X; Srivenugopal KS; Wang MH; Wang W; Zhang R
    Curr Med Chem; 2014; 21(5):553-74. PubMed ID: 24180275
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Fortifying p53 - beyond Mdm2 inhibitors.
    Sriraman A; Li Y; Dobbelstein M
    Aging (Albany NY); 2016 Sep; 8(9):1836-1837. PubMed ID: 27688014
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.